Jiangsu Aidea Pharmaceutical Group(688488.SH): Dolutegravir sodium tablets obtain drug registration approval.
Eddie Pharmaceuticals (688488.SH) issued an announcement. Recently, Jiangsu Eddie Pharmaceuticals Group Co., Ltd. received the "Drug Registration Certificate" for Dolutegravir Sodium Tablets approved and issued by the National Medical Products Administration ("NMPA") on March 10, 2026.
Jiangsu Aidea Pharmaceutical Group (688488.SH) announced that recently, Jiangsu Aidea Pharmaceutical Group Co., Ltd. received the "Drug Registration Certificate" for the sodium tablets of Dolutegravir approved and issued by the National Medical Products Administration (NMPA) on March 10, 2026.
The sodium tablets of Dolutegravir are a generic drug of the company's investment project - the HIV high-end generic drug research and development project sub-project ADC201 (Dolutegravir) formulation. Dolutegravir is an HIV-1 integrase chain transfer inhibitor, and its indication is in combination with other antiretroviral drugs for the treatment of HIV-infected adult and pediatric patients aged 12 and older.
Related Articles
Harbin Bank's 2026 "3.15" financial education campaign allows passengers to unlock new anti-fraud skills during their waiting time.
Subsidiary of Hunan Warrant Pharmaceutical (688799.SH) passed FDA onsite inspection at Chiral Drug Company
Kede Numerical Control (688305.SH) plans to jointly establish an Excellence Innovation Center with Shangfei Company.
Harbin Bank's 2026 "3.15" financial education campaign allows passengers to unlock new anti-fraud skills during their waiting time.
Subsidiary of Hunan Warrant Pharmaceutical (688799.SH) passed FDA onsite inspection at Chiral Drug Company
Kede Numerical Control (688305.SH) plans to jointly establish an Excellence Innovation Center with Shangfei Company.
